Repligen Corporation

Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.

Repligen reported second-quarter revenues of $204.1 million, up 11.9% year over year and exceeding analysts' expectations by 1.1%. The company also beat analysts' EPS and organic revenue estimates, with President and CEO Olivier Loeillot citing 13% organic growth and increased full-year guidance. Among the eight drug development inputs and services stocks tracked, the group's revenues beat consensus estimates by 4.1% on average, while next quarter's revenue guidance came in 0.8% above expectations. Repligen delivered the weakest performance against analyst estimates and the weakest full-year guidance update of the group, yet its stock is up 29.4% since reporting and currently trades at $169.56. Azenta posted the best Q2 with revenues of $161.2 million, up 12% year over year and beating estimates by 8%, while IQVIA reported revenues of $4.37 billion, up 8.7% year over year and exceeding expectations by 1.5%.

Repligen Corporation reported second-quarter revenue of $204.1 million, exceeding analyst expectations and marking an 11.9% year-on-year increase. The biopharma manufacturing company also posted adjusted earnings per share of $0.54, a 20.4% beat over consensus estimates, and raised its full-year revenue guidance to $824 million at the midpoint from $818 million. Organic revenue grew 13% year on year, reflecting sequential acceleration and continued market outperformance, according to CEO Olivier Loeillot. The company lifted its full-year adjusted EPS guidance to $2.06 at the midpoint, a 2.5% increase, and shares rose 4.2% to $136.50 following the announcement.

Payments firm Stripe is in discussions to acquire the AI startup OpenRouter for about $10 billion, headlining a busy week of dealmaking across multiple sectors. IBM intends to acquire quantum-focused research and development institution HRL Laboratories to aid its quantum computing efforts. Brookfield Asset Management agreed to buy battery storage developer Aypa Power for $7 billion including debt, and separately partnered with the Canada Pension Plan Investment Board to acquire LXP Industrial Trust in an all-cash transaction valued at about $5.2 billion including net debt and preferred equity. TE Connectivity announced it is acquiring privately held Astrodyne TDI in a $1.4 billion deal, while Repligen and BioLife Solutions entered into a definitive agreement under which Repligen will acquire BioLife for a total enterprise value of about $1.5 billion, comprised of 64% in Repligen common stock and 36% in cash. Magnolia Oil & Gas agreed to acquire closely held WildFire Energy for $4.06 billion in cash and stock including debt, and raised its quarterly dividend 9% to $0.18 per share. Var Energi agreed to acquire European rival BlueNord in a cash and stock deal valued at about $1.3 billion, creating Europe's largest independent oil and gas producer, while Arcadis rose 12% in Amsterdam trading after a report that the Dutch engineering consultancy received takeover interest from bidders including Canadian peer WSP Global.

President Donald Trump announced phased tariffs on generic drug imports, starting with zero tariffs for two years from August 1, then rising to 100% in August 2028 and 200% a year later, to push production onshore. Novo Nordisk sued Eli Lilly over ads comparing their GLP-1 weight-loss drugs, alleging misleading efficacy claims. Molina Healthcare shares fell about 11% despite beating second-quarter estimates, as its medical care ratio reached 92.2%. Repligen agreed to acquire BioLife Solutions for about $1.5 billion in a stock-and-cash deal. Roche shares jumped roughly 5% after the company reiterated its 2026 outlook, while Thermo Fisher Scientific raised its full-year guidance following better-than-expected second-quarter results.

Several biotech stocks reached 52-week highs on July 22, 2026, driven by clinical trial updates and acquisition news. Advanced Biomed shares surged over 73% to $18.73 after reporting a first-quarter net income of $5.98 million and disclosing a securities purchase agreement to acquire Accellent Technologies for approximately $1 million. BioLife Solutions rose over 6% to $31.49 following the announcement that Repligen would acquire the company for a total enterprise value of about $1.5 billion. Forte Biosciences gained over 11% to $56.84 after reporting positive Phase 1 vitiligo trial results for its lead product FB102, which is also in Phase 2 for celiac disease. Silence Therapeutics climbed over 9% to $11.90 as it prepares to begin a Phase 3 trial for its siRNA candidate Zerlasiran in high-risk atherosclerotic cardiovascular disease. LB Pharmaceuticals ended up over 10% at $36.59 after announcing that topline results from the Phase 3 NOVA-2 trial of its schizophrenia drug LB-102 would be reported in the first half of 2027, earlier than previously expected.

Repligen Corp. has agreed to acquire BioLife Solutions Inc. in a cash-and-stock deal valued at approximately $1.5 billion. The deal is priced at $31 per share, a 24% premium to BioLife's 90-day volume-weighted average price through July 21, with BioLife shareholders receiving $11.25 in cash and 0.1442 of a Repligen share for each BioLife share. The transaction is expected to close in the fourth quarter of 2026 and be accretive to Repligen's revenue growth, adjusted margins, and adjusted earnings per share, contributing at least $0.05 per share in the first year and $0.25 per share in the second year. Repligen also expects at least $20 million in synergies in year one and $30 million in year two, primarily from public company cost elimination, G&A efficiencies, and manufacturing and supply chain optimization, while retaining more than $300 million in pro forma cash and cash equivalents after closing. Preliminary second-quarter 2026 revenue for Repligen increased about 12% as reported and 13% organically from a year earlier, while BioLife reported preliminary second-quarter revenue of $28.5 million, up 21% from $23.4 million a year earlier.